Future Oncol

This plain language summary describes the results of the first study on subcutaneous (under the skin) injection of a medicine called isatuximab for people with multiple myeloma. Multiple myeloma is a type of blood cancer. Isatuximab is approved in various countries, to be given as an intravenous infusion (into a vein) alongside other medicines for people with multiple myeloma. Subcutaneous injection would reduce the time needed for the injection to take place and decrease the need for nurses to be involved. Isatuximab was given to some people with multiple myeloma as a subcutaneous injection, using a new type of injector called an on-body delivery system (OBDS for short). Other people with multiple myeloma received isatuximab intravenously. This would allow for researchers to compare the results. Everyone in the study also received treatment with pomalidomide and low-dose dexamethasone.